Chu Dapeng, Fu Lei, Zhou Wenhui, Li Yuan
a Medical Center for Human Reproduction , Beijing Chao-Yang Hospital, Capital Medical University , Beijing , People's Republic of China.
Syst Biol Reprod Med. 2018 Apr;64(2):138-145. doi: 10.1080/19396368.2017.1419510. Epub 2018 Jan 20.
The purpose of this study was to compare the efficacy of different open cryo-carriers: the CryoloopTM, CryotopTM, and CryoleafTM, in embryo survival and clinical outcome in patients with frozen embryo transfer (FET) cycle. We analyzed the embryo survival rate and clinical outcome in 325 patients of 348 FET cycles vitrified with the CryoloopTM (160 cycles), CryotopTM (105 cycles), or CryoleafTM (83 cycles). No significant differences were observed in embryo survival rate (98.8% vs. 100% vs. 97.7%, p > 0.05), HCG positive rate (58.8% vs. 63.8% vs. 57.8%, p > 0.05), biochemical pregnancy rate (6.9% vs. 11.4% vs. 9.6%, p > 0.05), or implantation rate (33.2% vs. 37.4% vs. 34.1%, p > 0.05) in the three groups respectively. The early abortion rate of the CryoloopTM group was significantly higher than that of the CryotopTM and CryoleafTM group (27.1% vs. 3.6% and 7.5%, p < 0.05). At the same time, the average female age of the CryoloopTM group was significantly older by 1 year than that of the CryotopTM and CryoleafTM group (33.29 ± 4.71 years vs. 31.96 ± 4.27 years and 31.1 ± 4.28 years, p < 0.05). There was no significant difference in take home baby rate (38.1% vs. 46.7% vs. 43.4, p > 0.05) or birth weight among the groups (2893.5 ± 780.8 g vs. 2778.4 ± 710.0 g vs. 2724.5 ± 838.8 g, p > 0.05). No case of neonatal malformation was observed in the present study. Overall, CryotopTM and CryoleafTM were effective for embryo vitrification at both the cleavage and blastocyst stage according to the results of clinical outcome and infant characteristics. However, CryoloopTM led to a decreased positive HCG rate and increased early abortion rate, heightened at the cleavage stage.
LN: liquid nitrogen; CPA: cryoprotectant; ART: assisted reproductive technology; IVF: in vitro fertilization; ICSI: intracytoplasmic sperm injection; BMI: body mass index; FSH: follicular stimulation hormone; COH: controlled ovarian hyperstimulation; FET: frozen embryo transfer; mm: millimeter; HCG: human chorionic gonadotropin; RCT: randomized clinical trial; NC: natural cycle; AC: artificial cycle; EM: equilibration medium; DMSO: dimethyl sulphoxide; EG: ethylene glycol; VM: vitrification medium; WM: warming medium.
本研究的目的是比较不同开放式冷冻载体（CryoloopTM、CryotopTM和CryoleafTM）在冷冻胚胎移植（FET）周期患者中的胚胎存活率和临床结局。我们分析了348个FET周期中325例患者的胚胎存活率和临床结局，这些患者的胚胎分别采用CryoloopTM（160个周期）、CryotopTM（105个周期）或CryoleafTM（83个周期）进行玻璃化冷冻。三组的胚胎存活率（98.8%对100%对97.7%，p>0.05）、HCG阳性率（58.8%对63.8%对57.8%，p>0.05）、生化妊娠率（6.9%对11.4%对9.6%，p>0.05）或着床率（33.2%对37.4%对34.1%，p>0.05）均未观察到显著差异。CryoloopTM组的早期流产率显著高于CryotopTM组和CryoleafTM组（27.1%对3.6%和7.5%，p<0.05）。同时，CryoloopTM组的平均女性年龄比CryotopTM组和CryoleafTM组显著大1岁（33.29±4.71岁对31.96±4.27岁和31.1±4.28岁，p<0.05）。各组的抱婴率（38.1%对46.7%对43.4，p>0.05）或出生体重（2893.5±780.8g对2778.4±710.0g对2724.5±838.8g，p>0.05）无显著差异。本研究未观察到新生儿畸形病例。总体而言，根据临床结局和婴儿特征结果，CryotopTM和CryoleafTM在卵裂期和囊胚期对胚胎玻璃化冷冻均有效。然而，CryoloopTM导致HCG阳性率降低和早期流产率增加，在卵裂期更为明显。
LN：液氮；CPA：冷冻保护剂；ART：辅助生殖技术；IVF：体外受精；ICSI：卵胞浆内单精子注射；BMI：体重指数；FSH：促卵泡激素；COH：控制性卵巢过度刺激；FET：冷冻胚胎移植；mm：毫米；HCG：人绒毛膜促性腺激素；RCT：随机临床试验；NC：自然周期；AC：人工周期；EM：平衡培养基；DMSO：二甲基亚砜；EG：乙二醇；VM：玻璃化培养基；WM：复温培养基。
